Mammary lymphoscintigraphy with various radiopharmaceuticals in breast cancer

Shigeru Imoto, Kohji Murakami, Hiroshi Ikeda, Hiroyoshi Fukukita, Noriyuki Moriyama

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Sentinel node biopsy (SNB) in breast cancer is a promising surgical technique that avoids unnecessary axillary lymph node dissection. To optimize lymphatic mapping with radiopharmaceuticals, mammary lymphoscintigraphy with 30-50 MBq of technetium-99m-diethylenetriamine pentaacetic acid human serum albumin ((99m)Tc-HSAD), technetium-99m-human serum albumin ((99m)Tc-HSA), or technetium-99m-tin colloid ((99m)Tc-TC) were investigated in 69 cases of primary breast cancer. Dynamic early images were obtained during the first 30 or 40 minutes, and static delayed images were obtained 6 hours after tracer injection. Hot spots as sentinel lymph nodes (SLNs) appeared in 51 of 69 cases (74%): in early images in 27 cases and in delayed images in 24 cases. SLNs were visualized more frequently in 23 of the 26 cases (88%) treated with (99m)Tc-HSAD and in 21 of the 24 cases (88%) treated with (99m)Tc-HSA than in only 7 of the 19 cases (37%) treated with (99m)Tc-TC. In 26 of the 51 cases, SLNs were identified as faint spots in delayed images. There was a significant difference in the first appearance of SLNs on the lymphoscintiscan between 43 cases of dense breast parenchyma and 26 cases of fatty breast parenchyma. These results suggest that (99m)Tc-HSAD or (99m)Tc- HSA is acceptable for lymphatic mapping, but in cases which have faint spots in delayed images or fatty breast parenchyma, gamma probe-guided SNB may result in failure or misleading false-negative SLNs.

Original languageEnglish
Pages (from-to)325-329
Number of pages5
JournalAnnals of Nuclear Medicine
Volume13
Issue number5
Publication statusPublished - 1999
Externally publishedYes

Fingerprint

Lymphoscintigraphy
Radiopharmaceuticals
Technetium Tc 99m Aggregated Albumin
Breast
Breast Neoplasms
Technetium
Serum Albumin
Technetium Tc 99m Pentetate
Biopsy
Lymph Node Excision
Sentinel Lymph Node
Injections

Keywords

  • Breast cancer
  • Breast parenchyma
  • Lymphoscintigraphy
  • Sentinel lymph node

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Imoto, S., Murakami, K., Ikeda, H., Fukukita, H., & Moriyama, N. (1999). Mammary lymphoscintigraphy with various radiopharmaceuticals in breast cancer. Annals of Nuclear Medicine, 13(5), 325-329.

Mammary lymphoscintigraphy with various radiopharmaceuticals in breast cancer. / Imoto, Shigeru; Murakami, Kohji; Ikeda, Hiroshi; Fukukita, Hiroyoshi; Moriyama, Noriyuki.

In: Annals of Nuclear Medicine, Vol. 13, No. 5, 1999, p. 325-329.

Research output: Contribution to journalArticle

Imoto, S, Murakami, K, Ikeda, H, Fukukita, H & Moriyama, N 1999, 'Mammary lymphoscintigraphy with various radiopharmaceuticals in breast cancer', Annals of Nuclear Medicine, vol. 13, no. 5, pp. 325-329.
Imoto S, Murakami K, Ikeda H, Fukukita H, Moriyama N. Mammary lymphoscintigraphy with various radiopharmaceuticals in breast cancer. Annals of Nuclear Medicine. 1999;13(5):325-329.
Imoto, Shigeru ; Murakami, Kohji ; Ikeda, Hiroshi ; Fukukita, Hiroyoshi ; Moriyama, Noriyuki. / Mammary lymphoscintigraphy with various radiopharmaceuticals in breast cancer. In: Annals of Nuclear Medicine. 1999 ; Vol. 13, No. 5. pp. 325-329.
@article{90e3e9a7f4af4c99909218f9f57997a3,
title = "Mammary lymphoscintigraphy with various radiopharmaceuticals in breast cancer",
abstract = "Sentinel node biopsy (SNB) in breast cancer is a promising surgical technique that avoids unnecessary axillary lymph node dissection. To optimize lymphatic mapping with radiopharmaceuticals, mammary lymphoscintigraphy with 30-50 MBq of technetium-99m-diethylenetriamine pentaacetic acid human serum albumin ((99m)Tc-HSAD), technetium-99m-human serum albumin ((99m)Tc-HSA), or technetium-99m-tin colloid ((99m)Tc-TC) were investigated in 69 cases of primary breast cancer. Dynamic early images were obtained during the first 30 or 40 minutes, and static delayed images were obtained 6 hours after tracer injection. Hot spots as sentinel lymph nodes (SLNs) appeared in 51 of 69 cases (74{\%}): in early images in 27 cases and in delayed images in 24 cases. SLNs were visualized more frequently in 23 of the 26 cases (88{\%}) treated with (99m)Tc-HSAD and in 21 of the 24 cases (88{\%}) treated with (99m)Tc-HSA than in only 7 of the 19 cases (37{\%}) treated with (99m)Tc-TC. In 26 of the 51 cases, SLNs were identified as faint spots in delayed images. There was a significant difference in the first appearance of SLNs on the lymphoscintiscan between 43 cases of dense breast parenchyma and 26 cases of fatty breast parenchyma. These results suggest that (99m)Tc-HSAD or (99m)Tc- HSA is acceptable for lymphatic mapping, but in cases which have faint spots in delayed images or fatty breast parenchyma, gamma probe-guided SNB may result in failure or misleading false-negative SLNs.",
keywords = "Breast cancer, Breast parenchyma, Lymphoscintigraphy, Sentinel lymph node",
author = "Shigeru Imoto and Kohji Murakami and Hiroshi Ikeda and Hiroyoshi Fukukita and Noriyuki Moriyama",
year = "1999",
language = "English",
volume = "13",
pages = "325--329",
journal = "Annals of Nuclear Medicine",
issn = "0914-7187",
publisher = "Springer Japan",
number = "5",

}

TY - JOUR

T1 - Mammary lymphoscintigraphy with various radiopharmaceuticals in breast cancer

AU - Imoto, Shigeru

AU - Murakami, Kohji

AU - Ikeda, Hiroshi

AU - Fukukita, Hiroyoshi

AU - Moriyama, Noriyuki

PY - 1999

Y1 - 1999

N2 - Sentinel node biopsy (SNB) in breast cancer is a promising surgical technique that avoids unnecessary axillary lymph node dissection. To optimize lymphatic mapping with radiopharmaceuticals, mammary lymphoscintigraphy with 30-50 MBq of technetium-99m-diethylenetriamine pentaacetic acid human serum albumin ((99m)Tc-HSAD), technetium-99m-human serum albumin ((99m)Tc-HSA), or technetium-99m-tin colloid ((99m)Tc-TC) were investigated in 69 cases of primary breast cancer. Dynamic early images were obtained during the first 30 or 40 minutes, and static delayed images were obtained 6 hours after tracer injection. Hot spots as sentinel lymph nodes (SLNs) appeared in 51 of 69 cases (74%): in early images in 27 cases and in delayed images in 24 cases. SLNs were visualized more frequently in 23 of the 26 cases (88%) treated with (99m)Tc-HSAD and in 21 of the 24 cases (88%) treated with (99m)Tc-HSA than in only 7 of the 19 cases (37%) treated with (99m)Tc-TC. In 26 of the 51 cases, SLNs were identified as faint spots in delayed images. There was a significant difference in the first appearance of SLNs on the lymphoscintiscan between 43 cases of dense breast parenchyma and 26 cases of fatty breast parenchyma. These results suggest that (99m)Tc-HSAD or (99m)Tc- HSA is acceptable for lymphatic mapping, but in cases which have faint spots in delayed images or fatty breast parenchyma, gamma probe-guided SNB may result in failure or misleading false-negative SLNs.

AB - Sentinel node biopsy (SNB) in breast cancer is a promising surgical technique that avoids unnecessary axillary lymph node dissection. To optimize lymphatic mapping with radiopharmaceuticals, mammary lymphoscintigraphy with 30-50 MBq of technetium-99m-diethylenetriamine pentaacetic acid human serum albumin ((99m)Tc-HSAD), technetium-99m-human serum albumin ((99m)Tc-HSA), or technetium-99m-tin colloid ((99m)Tc-TC) were investigated in 69 cases of primary breast cancer. Dynamic early images were obtained during the first 30 or 40 minutes, and static delayed images were obtained 6 hours after tracer injection. Hot spots as sentinel lymph nodes (SLNs) appeared in 51 of 69 cases (74%): in early images in 27 cases and in delayed images in 24 cases. SLNs were visualized more frequently in 23 of the 26 cases (88%) treated with (99m)Tc-HSAD and in 21 of the 24 cases (88%) treated with (99m)Tc-HSA than in only 7 of the 19 cases (37%) treated with (99m)Tc-TC. In 26 of the 51 cases, SLNs were identified as faint spots in delayed images. There was a significant difference in the first appearance of SLNs on the lymphoscintiscan between 43 cases of dense breast parenchyma and 26 cases of fatty breast parenchyma. These results suggest that (99m)Tc-HSAD or (99m)Tc- HSA is acceptable for lymphatic mapping, but in cases which have faint spots in delayed images or fatty breast parenchyma, gamma probe-guided SNB may result in failure or misleading false-negative SLNs.

KW - Breast cancer

KW - Breast parenchyma

KW - Lymphoscintigraphy

KW - Sentinel lymph node

UR - http://www.scopus.com/inward/record.url?scp=0032705333&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032705333&partnerID=8YFLogxK

M3 - Article

C2 - 10582802

AN - SCOPUS:0032705333

VL - 13

SP - 325

EP - 329

JO - Annals of Nuclear Medicine

JF - Annals of Nuclear Medicine

SN - 0914-7187

IS - 5

ER -